CARA - Cara Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
18.05
-0.38 (-2.06%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close18.43
Open18.48
Bid17.78 x 1400
Ask18.33 x 1100
Day's Range17.62 - 18.79
52 Week Range12.19 - 24.30
Volume1,183,159
Avg. Volume702,295
Market Cap717.516M
Beta (3Y Monthly)2.81
PE Ratio (TTM)N/A
EPS (TTM)-2.11
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.20
  • Thomson Reuters StreetEvents3 days ago

    Edited Transcript of CARA earnings conference call or presentation 7-May-19 8:30pm GMT

    Q1 2019 Cara Therapeutics Inc Earnings Call

  • Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use
    InvestorPlace3 days ago

    Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use

    Cannabis company Canopy Growth (NYSE:CGC) may have just secured its highest-profile celebrity endorsement yet. Perhaps only topped by the well-publicized relationship between Oprah Winfrey and Weight Watchers (NASDAQ:WW), lifestyle icon Martha Stewart just revealed she invested in an undisclosed stake in Canopy Growth stock because cannabis and cannabinol products are an "alternative to opioids."Source: Shutterstock She's probably not wrong. Insys Therapeutics (NASDAQ:INSY) and Cara Therapeutics (NASDAQ:CARA) are just a couple of several pharmaceutical companies developing ways to use the unique properties of the plant to make effective but not addictive pain-killers.Still, some industry experts are skeptical, and even if the CBD is the basis for an alternative to opioids the world hopes it will be, Canopy Growth role in that sliver of the cannabis movement is modest, at best. Its rise to prominence has been almost entirely driven by recreational use.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTake a closer look at the company though, and you'll find a handful of the (too many) different entities Canopy Growth owns are actually taking aim at the opioid epidemic. * 7 Safe Stocks to Buy for Anxious Investors Pain Relief and Canopy Growth StockThe 77-year Stewart is as in-touch with societal trends as any millennial is, recently explaining of her investment in Canopy Growth stock to Create & Cultivate's founder Jaclyn Johnson, "Well, it's the modern thing, and it's an alternative to opioids of course."It is indeed the modern thing to do. More than 60% of Americans now favor legalizing marijuana, and cannabis has promise as a strong pain reliever.The former model and TV show host went on to undermine her case, however, adding, "I have a lot of animals, and I would love to be able to relieve stress or arthritis or other kinds of problems that my horses, my dogs, my cats experience. We're working on that first, and we're working on additions to human food stuffs, and also on cosmetics."To-date, recreational marijuana has been the crux of the story surrounding Canopy Growth. Of its fiscal Q3 sales of 10,102 kilograms, up 334% year-over-year, the vast majority of it was for recreational usage.The company isn't ignoring its potential role as a supplier of cannabis for true medicinal purposes though. Pharma and Canopy Growth StockAs of the latest look, Canopy owns eight diverse brands, including the relatively new Spectrum Therapeutics, which serves as "the company's healthcare professional and patient-facing identity in medical markets in Canada and around the world." While new, the division has still been undersold.Spectrum Therapeutics is a three-branch unit. Canadian consumers are likely most familiar with Spectrum Cannabis, which supplies medical cannabis using a clever-though-not-complicated color-coding system.It's the other two divisions of Spectrum, however, that quietly look and feel more like pharma companies than a means of simply scoring a high.Canopy Health Innovations, for instance, has secured 38 provisional patents in the United States with more on the way. Overseas, it's involved in eleven different drug-development trials.Cannabinoid Compound Company, also referred to as C3, is Europe's largest cannabinoid-based pharmaceuticals company. Granted, that doesn't necessarily mean a whole lot just yet. The company's dronabinol, however, can be "prescribed by doctors in Germany for any type of chronic pain, and for any condition in palliative care."It's a credible start towards becoming the opioid alternative Martha Stewart believes is possible.Adding to that credibility is the fact that the NFL is exploring the use of cannabis as a means of treating players' pains. That follows a partnership forged between the NHL Alumni Association and Canopy Growth earlier this year, to explore cannabinoids as a means of treating post-concussion neurological diseases… an area the NFL should be exploring as well. Looking Ahead for Canopy Growth StockDon't misread the message. An investment in Canopy Growth stock is an investment in many things, but an investment in opioid alternatives is the least of them. And, it could take years for the prescription-based use of cannabis to catch up with Canopy's recreational business. If that's the impact Stewart is betting on, it could be a long and rocky wait.It's still on the radar though. And, with the opioid market expected to be worth roughly $35 billion by 2025, it's a prospect that would certainly make for a solid second-act from the company. Or, maybe a third act, if the United States legalizes marijuana at the federal level. While certainly game-changing, recreational usage can't drive double-digit and triple-digit growth forever.Besides, the bigger the recreational market gets, the more competitive it becomes, and we've already seen the prices of marijuana fall as it becomes increasingly commoditized.Prescription-based products, preferably co-developed with a major partner, could prove to be a key means for Canopy Growth to differentiate itself and establish a longer-lasting, better-defended growth engine. You've just heard very little about the potential opportunity because it's such a long-term one.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Safe Stocks to Buy for Anxious Investors * 4 Tech Stocks Looking Vulnerable * Should You Buy, Sell, Or Hold These 7 Hot IPO Stocks? Compare Brokers The post Even with a Pharma Arm, Canopy Growth Stock Is About Recreational Use appeared first on InvestorPlace.

  • 3 Small-Cap Biotech Stocks You Can Buy Right Now
    Motley Fool9 days ago

    3 Small-Cap Biotech Stocks You Can Buy Right Now

    They're risky. You'll have to wait years before any significant revenue comes in. But these biotech stocks could be huge winners.

  • Did Hedge Funds Drop The Ball On Casa Therapeutics Inc (CARA) ?
    Insider Monkey17 days ago

    Did Hedge Funds Drop The Ball On Casa Therapeutics Inc (CARA) ?

    At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of December 31. In this […]

  • GlobeNewswire18 days ago

    Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

    STAMFORD, Conn., May 08, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.

  • Cara Therapeutics Inc (CARA) Q1 2019 Earnings Call Transcript
    Motley Fool18 days ago

    Cara Therapeutics Inc (CARA) Q1 2019 Earnings Call Transcript

    CARA earnings call for the period ending March 31, 2019.

  • Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates
    Zacks19 days ago

    Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates

    Cara (CARA) delivered earnings and revenue surprises of -1.82% and -14.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press19 days ago

    Cara: 1Q Earnings Snapshot

    The Stamford, Connecticut-based company said it had a loss of 56 cents per share. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire19 days ago

    Cara Therapeutics Reports First Quarter 2019 Financial Results

    – Conference call today at 4:30 p.m. ET – STAMFORD, Conn., May 07, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and.

  • Key Cannabis Sector Updates: Analyst Ratings and Earnings
    Market Realist19 days ago

    Key Cannabis Sector Updates: Analyst Ratings and Earnings

    Key Cannabis Sector Updates: Price Action and Analyst Ratings(Continued from Prior Part)Cannabis updateLast week, Emerald Health Therapeutics (EMH) closed with losses of 9.4%. The company released its fourth-quarter and full-year 2018 earnings last

  • Cannabis Stocks Had a Mixed Performance Last Week
    Market Realist19 days ago

    Cannabis Stocks Had a Mixed Performance Last Week

    Key Cannabis Sector Updates: Price Action and Analyst RatingsCannabis stocksCannabis ETFs traded on a negative note last week. The Horizons Marijuana Life Sciences ETF (HMMJ) fell 1.2%, while the ETFMG Alternate Harvest ETF (MJ) gained 0.33%. The

  • Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options
    Zacks20 days ago

    Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options

    Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.

  • Top Marijuana Stocks on the NASDAQ
    Investopedia20 days ago

    Top Marijuana Stocks on the NASDAQ

    The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.

  • GlobeNewswire26 days ago

    Cara Therapeutics to Announce First Quarter 2019 Financial Results on May 7, 2019

    STAMFORD, Conn., April 30, 2019 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.

  • Ups and Downs in the Cannabis Space Last Week
    Market Realist27 days ago

    Ups and Downs in the Cannabis Space Last Week

    Cannabis Updates: Price Action, Ratings, and MoreCannabis spaceThe cannabis space was mostly positive last week. The Horizons Marijuana Life Sciences ETF (HMMJ) and the ETFMG Alternate Harvest ETF (MJ) gained 5.2% and 4.2%, respectively, while the

  • ETF Trends27 days ago

    Are There Cannabis Stocks in Your Portfolio? Here’s the Straight Dope

    As we approach April 20, a date that’s become something like a holiday for cannabis enthusiasts, there’s little argument that legalized marijuana is spreading like, well, a weed. Uruguay was the first country in the world to legalize cannabis for recreational use, in 2013, followed by Canada, which in 2018 became the world’s first developed nation to legalize recreational cannabis, having approved it for medicinal use back in 2001. In the United States, while it’s not legal at the federal level, as of the end of 2018 only four states have deemed cannabis to be illegal, with the majority of states approving it (as well as cannabidiol or “CBD,” the nonpsychoactive component of cannabis) for medicinal use.

  • Cannabis Updates: New Listings, Price Action, and Ratings
    Market Realistlast month

    Cannabis Updates: New Listings, Price Action, and Ratings

    Cannabis Updates: New Listings, Price Action, and RatingsCannabis updateThe cannabis sector showed some weakness last week, and the Horizons Marijuana Life Sciences ETF (HMMJ) lost 3.0% while the ETFMG Alternate Harvest ETF (MJ) lost 3.4%.

  • ACCESSWIRElast month

    CBD Company to Research Now

    HENDERSON, NV / ACCESSWIRE / April 16, 2019 / CBD is becoming a household name in the US. In a recent survey conducted with the Harris Poll, Quartz asked over 2,000 Americans about their use and perceptions ...

  • Better Buy: GW Pharmaceuticals vs. Cara Therapeutics
    Motley Foollast month

    Better Buy: GW Pharmaceuticals vs. Cara Therapeutics

    Both of these biotech stocks have tremendous momentum. Which is more likely to deliver bigger returns in the future?

  • ACCESSWIRElast month

    Cara Therapeutics Posts 2018 Revenue 15X over 2017, Questions, Catalysts, and Hurdles Every Marijuana Stock Investor Should be Considering

    NEW YORK, NY / ACCESSWIRE / April 11, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Cara Therapeutics, Inc. (CARA), a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors. Traders News Source has created a comprehensive report on the current state of the cannabis market, including an outlook on where the industry may be headed in 2019. This report is a must read for investors in cannabis stocks.

  • Why Cara Therapeutics Stock Jumped 15.1% in March
    Motley Fool2 months ago

    Why Cara Therapeutics Stock Jumped 15.1% in March

    This small biotech expects to announce results from two clinical studies in 2019.

  • 3 Top Biotech Stocks to Buy in April
    Motley Fool2 months ago

    3 Top Biotech Stocks to Buy in April

    These three biotech stocks are worth buying this month.

  • 3 Top Small-Cap Biotech Stocks for Aggressive Investors
    Motley Fool2 months ago

    3 Top Small-Cap Biotech Stocks for Aggressive Investors

    They're risky, but these up-and-coming biotechs could be tremendous winners for investors willing to take on those risks.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CARA earnings conference call or presentation 12-Mar-19 8:30pm GMT

    Q4 2018 Cara Therapeutics Inc Earnings Call

  • GlobeNewswire2 months ago

    Cara Therapeutics to Present at the 18th Annual Needham Healthcare Conference

    STAMFORD, Conn., April 02, 2019 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a.